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Abstract
Background: The emergence of endoscopic submucosal dis-
section (ESD) made possible en bloc resection of neoplastic 
gastric lesions, regardless of lesion size, with reduced rates of 
complications and recurrence. This technique has become 
the preferred method for curative resection, instead of con-
ventional endoscopic mucosal resection and surgery, when 
distant metastases have negligible risk. In Western countries 
experience with this technique has evolved quickly, with an 
increasing number of case series reported in the literature. 
This study aims to report the short- and long-term outcomes 
of ESD in gastric epithelial neoplastic lesions by a single op-
erator in a Portuguese centre. Methods: A retrospective anal-
ysis of all gastric ESDs in a tertiary specialised unit during a 
5-year period, between May 2012 and September 2017, was 
performed. Results: A total of 114 ESDs of gastric epithelial 
lesions were performed during this period; 96.5% of them 
were removed en bloc and 87.6% with R0 resection. A cura-
tive treatment was achieved in 83.2% of the cases. Complica-
tions occurred in 13.2% of the procedures, including early 
and delayed bleeding in 12 patients (10.5%) and one perfora-
tion (0.9%). With a median follow-up period of 12 months 
(interquartile range [IQR] = 18), 6 cases of recurrence at the 
previous ESD site were diagnosed: 4 residual lesions and 2 lo-
cal recurrences in previous R0 resections. Residual lesions oc-
curred more often in patients with larger lesions (median = 
40.0 mm, IQR = 26 vs. median = 20.0 mm, IQR = 15, p = 0.008) 
and with positive horizontal margins (HMs) after resection 
(50.0 vs. 0.0%, Fisher exact test, p < 0.001). The cumulative 
incidence of metachronous gastric lesions at 34 months was 
16.1%. All new lesions were effectively treated using an en-
doscopic technique. The disease-specific survival at 12 
months was 100%. Conclusion: This study showed that ESD 
is an effective resection technique for gastric lesions with a 
good safety profile, confirming other European series. Re-
gardless, high en bloc resection positive HM is still a problem 
in some specimens resected by ESD. Endoscopic surveillance 
can detect local recurrence and new lesions during early 
stages, potentially treatable by endoscopy.
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Disseção endoscópica da submucosa no tratamento 
da neoplasia epitelial gástrica num centro Português
Palavras Chave
Resseção endoscópica · Disseção submucosa · 
Endoscopia digestiva alta · Neoplasia epitelial gástrica ·  
Cancro gástrico precoce · Neoplasia intraepitelial de 
baixo grau · Neoplasia intraepitelial de alto grau
Resumo
Introdução: O aparecimento da dissecção endoscópica 
da submucosa (ESD) tornou possível a resseção em bloco 
de lesões neoplásicas superficiais do estômago, indepen-
dentemente da sua dimensão, com reduzidas taxas de 
complicações e recorrência. Esta técnica tem evoluído 
como método preferencial face à mucosectomia conven-
cional e cirurgia, quando a metastização à distância tem 
risco negligenciável. No mundo ocidental a experiência 
nesta técnica tem evoluído de forma rápida surgindo um 
número crescente de séries na literatura. Este estudo tem 
como objetivo reportar os resultados a curto e longo pra-
zo da ESD de lesões epiteliais gástricas realizadas por um 
único operador num centro Português. Metodologia: 
Análise retrospetiva unicêntrica dos casos de ESD de 
lesões epiteliais gástricas, realizadas durante um período 
de 5 anos, entre maio de 2012 e setembro de 2017. Resul-
tados: Foram realizadas 114 ESDs de neoplasias epiteliais 
gástricas durante o período em estudo, com uma taxa de 
resseção em bloco de 96.5% e R0 de 87.6%. A resseção 
curativa confirmou-se em 83.2% dos casos. Ocorreram 
complicações em 13.2% dos procedimentos, incluindo 
hemorragia em 12 doentes (10.5%) e 1 perfuração (0.9%). 
Com uma mediana de follow-up de 12 meses (variação 
interquartil [IQR] 18), verificaram-se 6 casos de recorrên-
cia local: 4 lesões residuais e 2 recorrências em resseções 
R0 prévias. Observaram-se mais frequentemente lesões 
residuais de ESD de lesões de maiores dimensões (me-
diana = 40.0 mm, IQR = 26 vs. mediana = 20.0 mm, IQR = 
15, p = 0.008) e com margens horizontais (HM) positivas 
após a resseção (50.0% vs. 0.0%, Teste exato de Fisher,  
p < 0.001). A incidência cumulativa de lesões gástricas me-
tácronas aos 34 meses foi de 16.1%. Todas as novas lesões 
foram eficazmente tratadas por endoscopia. A sobre-
vivência específica aos 12 meses de follow-up foi de 100%. 
Conclusão: Este estudo mostra que a ESD gástrica é uma 
técnica eficaz e segura para o tratamento de lesões neo-
plásicas precoces confirmando a maioria das séries euro-
peias. Embora a ESD permita geralmente uma resseção 
em bloco as HM positivas continuam a ser um problema 
em alguns doentes. A vigilância endoscópica pode de-
tetar recorrência local e novas lesões, em estádios preco-
ces, potencialmente tratáveis por endoscopia.
© 2018 Sociedade Portuguesa de Gastrenterologia 
Publicado por S. Karger AG, Basel
Introduction
Endoscopic submucosal dissection (ESD) is now wide-
ly accepted as the first approach in the treatment of early 
gastric cancer (EGC), if suitable for en bloc resection, and 
with a very low risk of lymph node metastasis [1, 2]. Ac-
cording to the Japanese Gastric Cancer Association and 
the European Society of Gastrointestinal Endoscopy, there 
are two different types of indications for ESD in the 
treatment of EGC (limited to the mucosa or the mucosa 
and submucosa): absolute and expanded indications [2, 
3]. The absolute criteria (differentiated mucosal cancers 
≤20 mm, without ulcerative findings and without lym-
phatic vascular invasion) for ESD in EGC were adapted 
from the endoscopic mucosal resection (EMR) indica-
tions, with higher rates of en bloc and complete resections 
with ESD [3, 4]. With the data from two large Japanese 
cancer centres, expanded indications were added to the 
Japanese guidelines in 2010 (differentiated mucosal can-
cers, without ulcerative findings and without lymphatic 
vascular invasion, regardless of tumour size; differentiated 
mucosal cancers, with ulcerative findings ≤30 mm and 
without lymphatic vascular invasion; differentiated min-
ute (< 500 µm) submucosal invasive cancers ≤30 mm with-
out lymphatic vascular invasion and undifferentiated mu-
cosal cancers ≤20 mm without ulcerative findings and 
without lymphatic vascular invasion) [5–8]. Nonetheless, 
in these cases, especially in undifferentiated cancers, ulcer-
ated or with minimal submucosal invasion, surgical treat-
ment should be discussed with patients because of poten-
tial lymph node metastasis and unsatisfactory prognosis 
[3]. Despite that, one of the largest Japanese consecutive 
patient series with a median follow-up period > 5 years did 
not show differences in survival rates between patients un-
dergoing curative ESD for absolute and expanded indica-
tions of EGC. The 5-year overall survival rates of the EGC 
patients with curative ESD for absolute indications and 
for expanded indications of differentiated-type EGC were 
93.0 and 92.2%, respectively, and the 5-year disease-specif-
ic survival rates of the EGC patients with curative ESD for 
absolute indications and for expanded indications of dif-
ferentiated-type EGC were both 99.9% [9].
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This study aims to report the short- and long-term 
outcomes of ESD in the treatment of gastric superficial 
epithelial neoplastic lesions in a Portuguese endoscopy 
unit, and to evaluate the risk factors for early local recur-
rence.
Patients and Methods
Patients and Study Design
All consecutive patients who underwent ESD for gastric neo-
plasia between May 2012 and September 2017 at Braga Hospital 
were analysed. Data from electronic patient files were collected, 
including demographic and clinical characteristics, endoscopies, 
treatments, and histology reports. Patients submitted to ESD with 
subepithelial lesions or large polyps and whose histopathology 
showed hyperplasia were excluded from this study (Fig. 1).
Description of the ESD Technique
Lesions were evaluated with a high-definition endoscope with 
virtual chromoendoscopy (narrow-band imaging) before the 
procedures, in order to establish the feasibility of endoscopic re-
section, the characterisation and delimitation of the lesion, and 
the decision on the best strategy. As a general rule, no additional 
complementary procedures such as endoscopic ultrasound or 
computed tomography were done before the endoscopic treat-
ment.
The morphology of the lesions was described according to the 
Paris classification. The location was assumed dividing the stom-
ach’s long axis into three segments – upper (cardia and fundus), 
middle (body and angle), and lower (antrum and prepylorus) – 
and the circular axis into four segments – lesser curvature, greater 
curvature, anterior wall, and posterior wall. The size was defined 
as the maximum diameter of the lesion.
Antiplatelet (clopidogrel/ticlopidine) and anticoagulant agents 
were always stopped according to the guidelines. Low-dose acetyl-
salicylic acid was only maintained in high-risk patients when indi-
cated by the cardiologist or vascular surgeon.
All ESDs were performed by a single operator with prior animal 
model experience and a 6-month period of training in a Portu-
guese endoscopy unit specialised in advanced endoscopic resec-
tion techniques. All procedures were done with a standard single-
channel scope (usually GIF-H180 or GIF-H185, and between 2012 
and 2015 episodically GIF-Q165; Olympus), an Erbe electrosurgi-
cal system (VIO 300 D), and under carbon dioxide insufflation. 
Most of the patients underwent general anaesthesia with orotra-
cheal intubation and the others were sedated with propofol. After 
identifying the target lesion, marks were made 5 mm laterally to 
the margin using argon plasma coagulation (Disposable Endo-
Probe, 2.3 mm, 600K0200; ARCO Söring) or a needle knife (KD-
10Q-1; Olympus). The submucosal injection was performed with 
a very dilute epinephrine solution (1: 250,000) in normal saline and 
a few drops of methylene blue. The initial mucosal incision was 
done with the needle knife (Endo Cut I mode, 60 W, effect 2) fol-
lowed by a circumferential mucosal incision with an insulated tip 
knife 2 (KD-611L; Olympus, Endo Cut I mode, 60 W, effect 3) and, 
finally, submucosal dissection using the same knife and settings. 
Endoscopic haemostasis was done with a Coagrasper (FD-410LR; 
Olympus, soft coagulation mode, 50 W, effect 4) and performed as 
needed during and after the procedure. A cap was only used in 
some difficult procedures to increase stability and help in endo-
scopic haemostasis. Finally, the resection site was covered with su-
crose sulfate-aluminium complex (sucralfate) (Fig. 2).
The patients were hospitalised under pantoprazole intravenous 
infusion (8 mg/h) for the first 48 h (which was then switched to 
oral intake, 40 mg twice a day for a total of 2 weeks) plus sucralfate. 
They usually started oral liquid diet 36–48 h after the procedure 
and were discharged on the next day (day 3 after the ESD) in the 
absence of complications.
Regarding complications, immediate bleeding was considered 
if there was intraoperative bleeding that required blood transfu-
sion or modification/suspension of the endoscopic treatment. Ear-
ly (< 24 h) and delayed (> 24 h) bleeding was considered if, during 
the postoperative period, haemorrhage (haematemesis, melena, or 
haematochezia) occurred or if there was a decrease in the haemo-
globin level > 2 g/dL, with need for blood transfusion or endoscop-
ic/surgical intervention. Minimal bleeding during the procedures 
was not accounted for and was managed with epinephrine injec-
tion or coagulation with the tip of the knife or a coagulation for-
ceps. Perforation was considered if it was endoscopically visible or 
if, under clinical indication, it was radiologically confirmed.
Histopathological Evaluation
The resected specimens were stretched and pinned to a poly-
styrene plate before being embedded in formaldehyde for fixation. 
Fragmented specimens were reconstituted to the greatest extent 
possible. Histology specimens were classified according to the 
World Health Organization classification of gastric epithelial neo-
plasia [10]. Cases showing both low-grade intraepithelial neoplasia 
(LGIN) and high-grade intraepithelial neoplasia (HGIN) were 
classified as HGIN. The diagnosis of intramucosal carcinoma was 
based on invasion of the lamina propria or muscularis mucosae by 
neoplastic epithelium.
Resection was defined as en bloc if the lesion was resected in 
one piece and as piecemeal if it was fragmented into two or more 





- 6 subepithelial lesions
- 3 benign polyps
123 gastric ESDs
(from May 2012 to September 2017)
114 gastric superficial
epithelial neoplastic lesions
Fig. 1. Study flow diagram. ESDs, endoscopic submucosal dissec-
tions.
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was en bloc and both horizontal margins (HMs) and vertical mar-
gins (VMs) were negative (HM0 and VM0, respectively). Incom-
plete resection (R1) was considered if the lesion was intercepted in 
at least one of the margins or in cases of piecemeal resection.
Resection was considered curative if all the following condi-
tions were fulfilled: R0 resection, no lymphovascular infiltration, 
and (1) tumours, irrespective of size, differentiated type, pT1a, 
without ulcerative findings, or (2) tumours < 3 cm, differentiated 
type, pT1a, with ulcerative findings, or (3) tumours < 3 cm, differ-
entiated type, pT1b (SM1 < 500 µm).
The patients with submucosal invasive cancers, regardless of 
curative resection, and all patients who did not fulfil the criteria for 
endoscopic curative resection were discussed in a multidisci-
plinary meeting, and surgical treatment (gastrectomy with lymph 
node dissection) was proposed eventually. In the cases of non-cu-
rative ESD where surgery was not considered the best option, new 
endoscopic treatment or stringent follow-up was the subsequent 
approach.
Follow-Up Schedule and Definitions
Surveillance endoscopy was performed 3 and/or 6 months after 
the ESD and every 12 months thereafter. Biopsies of the previous 
ESD site or suspicious areas in search for synchronous gastric le-
sions (SGLs) or metachronous gastric lesions (MGLs) were per-
formed during endoscopic surveillance. The follow-up period was 
defined as the period between the ESD and the last surveillance 
endoscopy.
In surveillance endoscopies, dysplasia or cancer found at the 
previous ESD site within 1 year was defined as residual disease and 
after more than 1 year as local recurrence. SGL and MGL were de-
fined as a new gastric neoplastic lesion that was detected during 
the first year and more than 1 year after ESD, respectively. Patients 
who did not undergo surveillance endoscopy were not considered 
for residual disease/local recurrence evaluation.
Statistical Analysis
Quantitative variables were presented as mean ± standard de-
viation or median and interquartile range (IQR) according to the 
presence of normal or non-normal distribution, respectively. Nor-
mality assessment was performed with the Shapiro-Wilk test (n < 
50) and the Kolmogorov-Smirnov test (n ≥ 50). Categorical vari-
ables were analysed using the χ2 test or the Fisher exact test, while 
numerical variables were analysed with the Student t test or the 
Mann-Whitney test, according to the presence or not of normality 
in the sample. The cumulative incidence of MGL development and 
overall survival rate were plotted using the Kaplan-Meier method. 
The confidence level was 95% and statistical significance was set at 
p < 0.05. All statistical analyses were performed with SPSS (version 
20.0; SPSS Inc., Chicago, IL, USA).
Results
A total of 105 patients with 114 gastric superficial epi-
thelial neoplastic lesions underwent ESD during the 5- 
year period (from May 2012 to September 2017).
Baseline Characteristics
The patients’ demographic and clinicopathological 
characteristics are described in Table 1. Most lesions were 
flat (95.6%), specifically types 0-IIa and 0-IIa+IIc of the 
Paris classification, and were located in the antrum 
(54.4%), followed by middle (38.6%) and proximal stom-
ach (7.0%). The median size of the lesions was 20.0 mm 
(IQR = 15; range, 5–60 mm). No ESD was performed for 
local recurrence of previous EMR.
Two patients were submitted to ESD without a previ-
ous biopsy, all type 0-IIa lesions that fulfilled the absolute 
indication criteria, and the decision was based on the cer-
tainty of the endoscopic diagnosis with magnification 
and narrow-band imaging. Moreover, in one ESD of a 
lesion whose previous biopsy had been negative for dys-
plasia, the posterior histopathology analysis of the resect-
ed specimen showed differentiated mucosal adenocarci-
noma.
Histological Features
En bloc resection was feasible in 96.5% (110/114), 
three were piecemeal resections (one of these in two piec-
a b c d
Fig. 2. a Superficial lesion in the lesser curvature of the gastric antrum measuring 25 mm (T0-Is+IIa). b Mucosal 
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es) and one ESD was not finished due to perforation (Ta-
ble 2). R0 was achieved in 87.6% (99/113): 96.6% (60/62) 
in the absolute indication group and 79.1% (34/43) in the 
expanded indication group. One ESD specimen was lost 
due to distal migration, therefore complete resection 
could not be evaluated and it was excluded from R0/R1 
assessment.
Eight resected lesions were classified beyond the ex-
panded criteria. All of them were differentiated submu-
cosal invasive cancers in which submucosal invasion was 
> 500 µm or SM invasion was impossible to measure. Six 
of the lesions had a previous biopsy that showed only dys-
plasia and did not have morphologic features suggesting 
endoscopic unresectability. The other two were adeno-
carcinomas (on biopsy), < 30 mm, and had previously 
been discussed in a multidisciplinary meeting. Endoscop-
ic resection was decided based on the patients’ general 
poor condition.
Adverse Events
Bleeding occurred in 12 procedures (10.5%): 4 cases 
of early bleeding (< 24 h) and 8 cases of delayed bleeding 
(> 24 h) (Table 2). No significant immediate bleeding oc-
curred during the procedures. All haemorrhages were 
treated endoscopically: single injection of a dilute solu-
tion of epinephrine (1: 10,000) was used in 2 cases (16.7%); 
placement of endoclips with or without a previous epi-
nephrine injection was performed in 8 cases (66.7%); 1 
bleeding vessel was treated with adrenaline plus polido-
canol injections (8.3%); and in 1 case (8.3%) the bleeding 
was controlled only after the use of haemostatic powder 
(Hemospray®; Cook Medical). Three patients needed 
blood transfusions, and 1 patient was admitted to the in-
tensive care unit for 1 day because of haemorrhagic shock 
after ESD of a lesion located in the cardia. One perfora-
tion (0.9%) occurred during an ESD of a lesion in the car-








Family history of gastric cancer 21 (25.6%)
Previous endoscopic treatment for gastric epithe-
lial neoplasia in other locations than index ESD: 








































Location in the stomach – longitudinal axis
Upper third (cardia and fundus)

























Absence of extensive atrophic gastritis
Presence of extensive atrophic gastritis
38 (33.3%)
76 (66.7%)
Data are presented as mean ± standard deviation, median (in-
terquartile range), n, or n (%). EMR, endoscopic mucosal resec-
tion; ESD, endoscopic submucosal dissection; HGIN, high-grade 
intraepithelial neoplasia; LGIN, low-grade intraepithelial neopla-
sia. 1 Physical status classification system. 2 Paris classification.
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the procedure was stopped since en bloc resection was 
compromised due to technical difficulties. The patient 
was subsequently referred for surgical treatment (gastrec-
tomy). No procedure-related death was observed.
Short-Term Outcomes
Curative endoscopic resection was achieved in 83.2% of 
all patients. A positive HM was observed in 10 specimens 
(8.9%) and occurred more often in patients who did not 
Table 2. Outcomes


























































Positive horizontal margins 10 (8.9%) 1 (1.6%) 8 (18.6%) 0.003



































Inpatient time, days 3 (1)
Curative resection 94 (83.2%) 60 (96.8%) 34 (79.1%) 0.007
Surgery 7 (6.1%)
















Metachronous lesions 3/37 (8.1%) 2 (9.1%) 1 (6.7%) 1.000
Data are presented as n, n (%), or median (interquartile range). HGIN, high-grade intraepithelial neoplasia; 
LGIN, low-grade intraepithelial neoplasia. 1 Total of 112 because 1 missing lesion and 1 ESD were not finished. 
2 Previous LGIN on biopsy. 3 Pneumonia occurred in a patient with a lesion beyond the expanded criteria.
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fulfil the absolute indication criteria (Table 2). Dividing the 
study time into two periods, 2012–2015 and 2016–2017, a 
tendency towards improvement in HM results was found, 
although without statistical significance (11.9% [7/59] pos-
itive HM in 2012–2015 vs. 5.7% [3/53] in 2016–2017, Fish-
er exact test, p = 0.328). In a total of 10 patients with adeno-
carcinoma and non-curative endoscopic resection, 6 un-
derwent surgical treatment with total or partial gastrectomy, 
but only 1 patient had residual neoplasia after histopatho-
logical assessment of the surgical specimen. In the 4 patients 
who were not submitted to surgery, one local recurrence 
was observed. It occurred in a patient with a previous frag-
mented resection and was successfully treated by endos-
copy. One 90-year-old man with R1 resection (VM+ and 
HM+) and lymphovascular invasion refused any addition-
al surveillance or treatment. Another patient with an R0 
resection but with submucosal invasion > 500 µm refused 
additional surgical treatment and remained under endo-
scopic and imaging follow-up without signs of disease re-
currence. The last patient was considered unfit for surgical 
treatment (78-year-old male, ASA IV) and remains under 
endoscopic follow-up without any signs of disease recur-
rence and with two more lesions treated by ESD.
Long-Term Outcomes
During a median follow-up of 12 months (IQR = 18), 
6 cases of recurrence were diagnosed: 4 residual lesions 
(1 intramucosal adenocarcinoma resected in piecemeal 
and 3 HGINs with R1 resections due to positive HM) and 
2 local recurrences in previous R0 resections (1 minimal-
ly invasive submucosal adenocarcinoma and 1 LGIN). 
The recurrent tissue was dysplastic and non-invasive in 
all cases. Residual lesions were treated with argon plasma 
coagulation, one local recurrence with EMR, and the oth-
er local recurrence was lost to follow-up. Residual lesions 
were observed more often in patients with larger lesions 
and with positive HMs when compared to smaller lesions 
(median = 40.0 mm, IQR = 26 vs. median = 20.0 mm, 
IQR = 15, p = 0.008) and R0 resection (50.0 vs. 0.0%, Fish-
er exact test, p < 0.001), respectively.
Three patients had been previously submitted to EMR 
for other gastric epithelial neoplastic lesions in different 
locations. During the surveillance period, 7 SGLs were 
observed and 3 MGLs were identified (Table 2). The cu-
mulative incidence of MGLs at 34 months was 16.1% 
(Fig. 3). All lesions were removed with a repeat ESD.
Overall survival was 96%, but disease-specific survival 
was 100%, with a median follow-up of 12 months (IQR = 
18). Four patients died during the follow-up period due 
to non-cancer-related causes (cerebrovascular accident, 
cirrhosis decompensation, end-stage pulmonary disease, 
and sudden death).
Discussion
ESD is a technique which was introduced in the last 
decade in Western countries that implies a high level of 
expertise, with outcomes still slightly inferior to those 
from Eastern series [11].
The current study represents a retrospective descrip-
tion of superficial epithelial gastric neoplasias treated by 
ESD in a single centre and the second largest Portuguese 
case series report published [12–14]. The outcomes were 
similar to the results presented in the literature, with an 
en bloc R0 resection rate reaching 90% and a cure rate of 
> 80%, with a good safety profile [14, 15]. All adverse 
events (10.5% rate of bleeding and 0.9% rate of perfora-
tion) were controlled endoscopically and none of the pa-
tients needed surgery. After resection, a careful inspec-
tion of the resection site was done along with prophylac-
tic coagulation of all visible vessels. The ulcer was covered 
with sucralfate, a gastroprotective agent that directly 
binds the gastric submucosa in the ulcer bed, providing a 
physical barrier against gastric irritants. Although there 
is no evidence regarding the use of sucralfate in ESD, re-
cent studies have employed sucralfate as a topical drug for 
the healing of several types of epithelial wounds such as 
ulcers, mucositis, and burn wounds [16, 17].
Fragmented resection and positive HM are associated 

























Fig. 3. Cumulative incidence of metachronous gastric lesions 
(MGLs).
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around 10–30% [3]. Although ESD allows a high en bloc 
resection rate, positive HMs are sometimes encountered 
(a Japanese multicentre survey reported 2% positive HMs 
in differentiated-type gastric adenocarcinomas). Appro-
priate treatment strategies for differentiated-type gastric 
cancers with positive HMs or indeterminable margins af-
ter ESD have not yet been established in guidelines [18]. 
Moreover, non-surgical options may be proposed due to 
a low risk of lymph node metastasis [3, 18]. In this study, 
a 4.9% rate of residual recurrence and a 5.3% rate of local 
recurrence were reported. In patients with positive HMs 
on resected specimens, 50% had residual disease, which 
is higher than in previous studies, even though all resid-
ual lesions were managed endoscopically [18, 19].
Some retrospective studies have tried to identify risk 
factors to positive HMs [19–21]. Kakushima et al. [20] 
reported three main reasons for positive HMs after resec-
tion: lesions with a flat spreading area not included in the 
marking, lesions with an unexpected nearby lesion, and 
lesions with lateral extension in the submucosa under a 
non-cancerous mucosa. After that, Sekiguchi et al. [19] 
identified a cancer-positive lateral margin length ≥6 mm 
as an independent risk factor for local recurrence after 
ESD (with a sensitivity and specificity for a 5-year risk of 
developing local recurrence of 66.7 and 95.6 %, respec-
tively). Recently, Numata et al. [21] recognised that loca-
tion of the tumour in the upper third of the stomach and 
lesions not matching the absolute indication criteria were 
independent risk factors for positive HMs. In this study, 
expertise with digital chromoendoscopy improved along 
with the ESD learning curve, and the regular use of high-
definition endoscopy in the last period can partially ex-
plain highly positive HMs in the beginning. Secondly, no 
treatment was done in positive HMs before residual le-
sion detection. Maybe high-risk patients need to be treat-
ed promptly and the length of cancer-positive HM can 
help to decide which ones need additional treatment [19].
Two cases of R0 resections (minimally invasive sub-
mucosal adenocarcinoma and LGIN) developed local re-
currence. After a careful revision of the endoscopic and 
histological records, male sex was identified in both cases 
as well as narrow lateral margin on the first lesion and 
extensive atrophic gastritis on the second, all risk factors 
for local recurrence [22, 23].
Patients without endoscopic curative resection crite-
ria, besides positive HMs, were sent to surgery for cura-
tive treatment, but only 1 patient from those submitted to 
gastrectomy had residual neoplasia with lymph node me-
tastasis after histopathological assessment. This study 
confirmed the low risk of lymph node metastasis in ex-
panded criteria patients and ESD as the best staging tool 
before surgery for EGC [3, 9, 15]. However, when lesions 
were divided into two groups of indications (absolute ver-
sus expanded indications), the second group presented 
lower rates of R0 (96.6 vs. 79.1%, p = 0.007) and curative 
resection (96.8 vs. 79.1%, p = 0.007), with an increased 
residual lesion rate (0 vs. 13.3%, p = 0.024), confirming a 
recent meta-analysis [24], although endoscopically treat-
able in most of the cases.
Seven SGLs were detected during the first year, possibly 
missed before or at the time of the ESD, and 3 MGLs during 
the remaining follow-up period [25]. Regardless of endo-
scopic treatment being less invasive and associated with 
better quality of life compared to surgery, preservation of 
the stomach carries a greater risk of other gastric cancers. 
Some studies report an annual incidence of 1–3% for other 
gastric cancers, and the cumulative incidence of MGLs con-
stantly increased, at least during the first 3–5 years [4, 14, 
23, 25]. Recently, one retrospective study showed that pa-
tients with SGLs or male patients with extensive intestinal 
metaplasia have a high risk of MGLs even after 5 years [25]. 
So, endoscopic surveillance is necessary and short intervals 
(≤12 months) detect more endoscopically treatable lesions, 
decreasing the need for surgery [23, 25]. Currently, there is 
still not sufficient evidence to decide when to stop surveil-
lance in patients submitted to ESD for EGC.
Overall survival was 96%, with four deaths during the 
follow-up period due to non-cancer-related causes, but 
disease-specific survival was 100%. This may be explained 
by the application of this endoscopic technique to many 
patients who seem unfit for major surgery due to old age 
or significant morbidities.
The study has some limitations. Firstly, the median 
follow-up was short and consequently the long-term out-
comes should be interpreted with caution. Secondly, pro-
cedure duration, which could be a good tool to evaluate 
operator efficiency, was not evaluated, even though 83.2% 
of the lesions were successfully treated by ESD. Lastly, 
LGIN and HGIN (besides adenocarcinoma) were includ-
ed in the study, and the results were compared with those 
of Eastern studies; however, the differences in histopath-
ological classifications in Western and Eastern countries 
raise some questions regarding these comparisons.
In conclusion, the study results showed that ESD is an 
effective resection technique for gastric lesions with a 
good safety profile, confirming other European series. 
Regardless of a high en bloc resection, positive HM is still 
a problem in some specimens resected by ESD. Endo-
scopic surveillance could detect local recurrence and new 
lesions in early stages potentially treatable by endoscopy.
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